GlassScriptPhysician profile
Jennifer Ozan
NPI 1154633394
$11,444.77
in general payments reported to CMS, 2019-2025
28 companies · $381 in 2025
The $381 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $622 · 2020: $547 · 2021: $461 · 2022: $263 · 2023: $743 · 2024: $8,428 · 2025: $381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,962 · Travel and Lodging: $3,617 · Food and Beverage: $972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,962.02 |
| Travel and Lodging | $3,617.39 |
| Food and Beverage | $972.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,364.08 | 2024-2025 | |
| Abbvie INC. | $661.04 | 2019-2023 | |
| Astellas Pharma US INC | $539.91 | 2023-2025 | Veozah |
| Pfizer INC. | $336.36 | 2019-2024 | |
| Therapeuticsmd, INC. | $250.62 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $157.50 | 2019-2025 | |
| Daiichi Sankyo INC. | $155.03 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.53 | 2020-2025 | |
| Exeltis, USA INC. | $113.38 | 2019-2024 | Slynd |
| Sumitomo Pharma America, INC. | $79.30 | 2023-2024 | Myfembree, Gemtesa |
| Evofem Biosciences, INC. | $74.39 | 2021-2025 | Solosec, Phexx, Phexxi |
| Novo Nordisk INC | $72.55 | 2019-2023 | Wegovy |
| Merck Sharp & Dohme LLC | $57.38 | 2019-2023 | Gardasil 9 |
| Mylan Pharmaceuticals INC. | $52.94 | 2019-2020 | |
| Avion Pharmaceuticals | $51.24 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $48.25 | 2019-2020 | |
| Davol INC. | $44.72 | 2020 | |
| Hologic Sales and Service, LLC | $38.89 | 2021-2025 | Fetal Fibronectin Enzyme Immunoassay |
| Amag Pharmaceuticals, INC. | $27.95 | 2019 | |
| Coopersurgical, INC. | $27.94 | 2019 | |
| Duchesnay USA Incorporated | $27.31 | 2019 | |
| Lupin INC. | $25.77 | 2020 | |
| Organon LLC | $25.02 | 2022 | |
| Dilon Technologies, INC. | $22.97 | 2025 | Hemoblast Bellows |
| Millicent US INC | $20.81 | 2025 | Femlyv |
| Roche Diagnostics Corporation | $17.97 | 2019 | |
| Shield Therapeutics INC | $15.08 | 2023 | Accrufer |
| Myovant Sciences INC. | $14.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Ozan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.